Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.74 |
| ▸ | TK1 | P04183 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265601 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL6075436 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL27444298 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL31289437 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL15187886 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL15498284 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL12932156 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL15498298 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL8659547 | 0.90 | RNASE1 (0.62) | RNASE1TK1 | |
| SCHEMBL8659542 | 0.90 | RNASE1 (0.62) | RNASE1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59141591-A | — | — | None | — | — | JP | disclosed |
| US-20240425543-A1 | Synthesis and Biological Activity of Phosphoramidimidate and Phosphoramidate DNA | UNIV COLORADO REGENTS (US) | 2024-12-26 | — | — | US | disclosed |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2024-06-20 | — | — | US | disclosed |
| US-20220025432-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | FUTURESYNTHESIS SPÓLKA Z O.O. (PL) | 2022-01-27 | — | — | US | disclosed |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210277047-A1 | Synthesis and Biological Activity of Phosphoramidimidate and Phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-20210254059-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| EP-3187584-B1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | JAPAN SCIENCE & TECH AGENCY (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-0378615-A4 | NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES | — | 1992-04-08 | — | — | EP | disclosed |
| EP-0463712-A2 | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections | UNIVERSITY PATENTS, INC. (US) | 1992-01-02 | — | — | EP | disclosed |
| WO-1991004983-A1 | NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES | UNIVERSITY PATENTS, INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| EP-0411186-A1 | DNA probe assay using neutrally charged probe strands | ABBOTT LABORATORIES (US) | 1991-02-06 | — | — | EP | disclosed |
| WO-1990012022-A1 | POLYNUCLEOTIDE PHOSPHORODITHIOATES AS THERAPEUTIC AGENTS FOR RETROVIRAL INFECTIONS | UNIVERSITY PATENTS, INC. (US) | 1990-10-18 | — | — | WO | disclosed |
| EP-0378615-A1 | NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES | COMPETITIVE TECHNOLOGIES INC. (US) | 1990-07-25 | — | — | EP | disclosed |
| WO-1989011486-A1 | NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES | UNIVERSITY PATENTS, INC. (US) | 1989-11-30 | — | — | WO | disclosed |
| WO-1989009779-A1 | PHOSPHORAMIDITE REAGENT FOR CHEMICAL SYNTHESIS OF MODIFIED DNA | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRE (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4469863-A | ANTITUMOR AGENTS, VIRICIDES | GENTA INCORPORATED | 1984-09-04 | — | — | US | disclosed |
| JP-S59141591-A | PREPARATION OF AMMONIUM (5-IODO-3-INDOLYL) 5'-THYMIDYLATE | FUJIREBIO INC | 1984-08-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | RNASE1 2/4885TK1 10/4885LMNA 995/4885 |
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | RNASE1 156/4885TK1 150/4885LMNA 319/4885 |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | RNASE1 70/4885TK1 152/4885LMNA 311/4885 |
| US-20220025432-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | DUT, NOP2, NUDT1 | RNASE1 36/4885TK1 7/4885LMNA 302/4885 |
| US-20240425543-A1 | Synthesis and Biological Activity of Phosphoramidimidate and Phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | RNASE1 2/4885TK1 10/4885LMNA 995/4885 |
| US-20210277047-A1 | Synthesis and Biological Activity of Phosphoramidimidate and Phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | RNASE1 2/4885TK1 10/4885LMNA 995/4885 |
| US-20210254059-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | SYNCRIP, HNRNPA3, HNRNPA2B1 | RNASE1 28/4885TK1 559/4885LMNA 102/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | RNASE1 70/4885TK1 152/4885LMNA 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.